Belite plans filing for oral Stargardt drug after phase 3 win The first therapy for sight-robbing Stargardt disease could be on the way, as Belite Bio's tinlarebant hits the mark in a phase 3 trial.

#BeliteBio has said the results of the DRAGON trial of its oral therapy for sight-robbing disorder #Stargardtdisease type 1 (STGD1), tinlarebant, could support an FDA filing. #retinaldisease

pharmaphorum.com/news/belite-...